Document is current

Article History

Received: 17 January 2025

Accepted: 1 June 2025

First Online: 14 June 2025

Declarations

:

: JP is a consultant for Amgen, Apellis Pharmaceuticals Inc., Bristol Myers Squibb, MSD, and Sanofi Ltd; participated in speakers’ bureaus for Alexion, Boehringer Ingelheim, Blueprint Medicines, F. Hoffmann-La Roche Ltd, Novartis, Pfizer, Samsung Bioepis, and Sobi; and is a member on the Board of Directors or advisory committee of Alexion, Boehringer Ingelheim, Blueprint Medicines, F. Hoffmann-La Roche Ltd, Novartis, Omeros, Samsung Bioepis, and Sobi. BH received honoraria from AstraZeneca, F. Hoffmann-La Roche Ltd, and Novartis; and research funding from F. Hoffmann-La Roche Ltd and Novartis. FAGF is a consultant for Alexion AstraZeneca Rare Disease, F. Hoffmann-La Roche Ltd, Novartis, and Sobi; received honoraria from Alexion AstraZeneca Rare Disease, F. Hoffmann-La Roche Ltd, Novartis, and Sobi; and participated in speakers’ bureaus for Alexion AstraZeneca Rare Disease, F. Hoffmann-La Roche Ltd, Novartis, and Sobi. AG is a consultant for Alexion, Asahi Kasei, Chugai, and PharmaEssentia Japan; received honoraria from AbbVie, Alexion, AstraZeneca, Asahi Kasei, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Janssen Pharmaceutical, Kyowa Kirin, Nihon Pharmaceutical, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer Japan, PharmaEssentia Japan, Sanofi, Sumitomo Pharmaceutical, Taiho Pharmaceutical, and Takeda Pharmaceutical; received research funding from Asahi Kasei, Chugai, Ono Pharmaceutical, Otsuka Pharmaceutical, and Taiho Pharmaceutical. AGK has received honoraria from Agios, Alexion AstraZeneca Rare Disease, Amgen, Celgene/Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Pfizer, and Ra Pharma/UCB; is on the Board of Directors or is an advisory board member for Agios, Alexion AstraZeneca Rare Disease, Amgen, Celgene/Bristol Myers Squibb, Geron, Novartis, F. Hoffmann-La Roche Ltd, and Ra Pharma; and has received consultancy fees from Achillion, Agios Pharmaceuticals, Akari Therapeutics, Alexion AstraZeneca Rare Disease, BioCryst, Celgene/Bristol Myers Squibb, Novo Nordisk, Janssen Pharmaceuticals, F. Hoffmann-La Roche Ltd, Samsung, and Novartis. PS is a consultant for Alexion AstraZeneca Rare Disease, Novartis, Pfizer, and F. Hoffmann-La Roche Ltd; has given scientific presentations for Alexion AstraZeneca Rare Disease, Bristol Myers Squibb, Janssen, Novartis, and F. Hoffmann-La Roche Ltd; and received research funding from Alnylam and Pfizer. HS received honoraria from Alexion, Amgen, Novartis, Omeros Corporation, Sanofi, and Sobi; is a member on the advisory committee of Alexion, Novartis, Omeros Corporation, Sanofi, and Sobi; and participated in speakers’ bureaus for Alexion, Novartis, Sanofi, and Sobi (all payments to the institution, University Hospital Ulm). NS has received honoraria from Alexion, Amgen, and Sobi. YU is a consultant for Alexion AstraZeneca Rare Disease, Asahi Kasei, Chugai Pharmaceutical, Janssen, Novartis, Sanofi, and Sobi; is on the Board of Directors or is an advisory board member for Alexion AstraZeneca Rare Disease, Novartis, and Sanofi; has received honoraria from Alexion AstraZeneca Rare Disease, Chugai Pharmaceutical, and Sobi; received research funding from Chugai Pharmaceutical; and has participated in speakers’ bureaus for Alexion AstraZeneca Rare Disease, Novartis, and Sanofi. ACC is a current employee of Genentech, Inc. BG was an employee of Genentech, Inc. JS and MU are current employees of F. Hoffmann-La Roche Ltd. AR reports consultancy for Alexion, Amgen, Apellis, BioCryst, Bioverativ, Kira, Novartis, Pfizer, Roche, and Sanofi; research funding from Roche; honoraria from Alexion, Bioverativ, Grifols, Roche, Novartis, and Sanofi; advisory committee for Alexion, Apellis, BioCryst, Novartis, Roche, and Sanofi. JC, OK, and FS have no disclosures to declare.